{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T17:13:56Z","timestamp":1789233236938,"version":"build-2803163510"},"reference-count":119,"publisher":"Pharmaceutical Society of Japan","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological & Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2026,6,1]]},"DOI":"10.1248\/bpb.b26-00057","type":"journal-article","created":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T22:11:36Z","timestamp":1780265496000},"page":"896-909","source":"Crossref","is-referenced-by-count":1,"title":["Organ Crosstalk in CKD-Associated Frailty: Mechanistic Insights, Translational Opportunities, and Clinical Implications"],"prefix":"10.1248","volume":"49","author":[{"given":"Hiroshi","family":"Watanabe","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Kitazato","sequence":"additional","affiliation":[{"name":"Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Hirashima","sequence":"additional","affiliation":[{"name":"Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Enoki","sequence":"additional","affiliation":[{"name":"Division of Pharmacodynamics, Faculty of Pharmacy, Keio University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromasa","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Pharmacokinetics, School of Pharmacy and Pharmaceutical Sciences, Hoshi University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Ochiai","sequence":"additional","affiliation":[{"name":"Department of Pharmacokinetics, School of Pharmacy and Pharmaceutical Sciences, Hoshi University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University"},{"name":"Graduate School of Pharmaceutical Sciences, Kyoto Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoko","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Akebono Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Matsushita","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Akebono Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Taylor JA, Greenhaff PL, Bartlett DB, Jackson TA, Duggal NA, Lord JM. Multisystem physiological perspective of human frailty and its modulation by physical activity. Physiol. Rev.<\/i>, 103<\/b>, 1137\u20131191 (2023).","DOI":"10.1152\/physrev.00037.2021"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Soto ME, P\u00e9rez-Torres I, Rubio-Ruiz ME, Cano-Mart\u00ednez A, Manzano-Pech L, Guarner-Lans V. Frailty and the interactions between skeletal muscle, bone, and adipose tissue-impact on cardiovascular disease and possible therapeutic measures. Int. J. Mol. Sci.<\/i>, 24<\/b>, 4534 (2023).","DOI":"10.3390\/ijms24054534"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Kooman JP, Kotanko P, Schols AM, Shiels PG, Stenvinkel P. Chronic kidney disease and premature ageing. Nat. Rev. Nephrol.<\/i>, 10<\/b>, 732\u2013742 (2014).","DOI":"10.1038\/nrneph.2014.185"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Tian YE, Cropley V, Maier AB, Lautenschlager NT, Breakspear M, Zalesky A. Heterogeneous aging across multiple organ systems and prediction of chronic disease and mortality. Nat. Med.<\/i>, 29<\/b>, 1221\u20131231 (2023).","DOI":"10.1038\/s41591-023-02296-6"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Watanabe H, Enoki Y, Maruyama T. Sarcopenia in chronic kidney disease: factors, mechanisms, and therapeutic interventions. Biol. Pharm. Bull.<\/i>, 42<\/b>, 1437\u20131445 (2019).","DOI":"10.1248\/bpb.b19-00513"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Nishi H, Takemura K, Higashihara T, Inagi R. Uremic sarcopenia: clinical evidence and basic experimental approach. Nutrients<\/i>, 12<\/b>, 1814 (2020).","DOI":"10.3390\/nu12061814"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Freire-Filho WA, Dalboni MA, Elias RM. Effects of aging on chronic kidney disease mineral and bone disorder. Curr. Opin. Nephrol. Hypertens.<\/i>, 34<\/b>, 297\u2013303 (2025).","DOI":"10.1097\/MNH.0000000000001084"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Michou V, Tsamos G, Vasdeki D, Deligiannis A, Kouidi E. Unraveling of molecular mechanisms of cognitive frailty in chronic kidney disease: how exercise makes a difference. J. Clin. Med.<\/i>, 13<\/b>, 5698 (2024).","DOI":"10.3390\/jcm13195698"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Wathanavasin W, Banjongjit A, Avihingsanon Y, Praditpornsilpa K, Tungsanga K, Eiam-Ong S, Susantitaphong P. Prevalence of sarcopenia and its impact on cardiovascular events and mortality among dialysis patients: a systematic review and meta-analysis. Nutrients<\/i>, 14<\/b>, 4077 (2022).","DOI":"10.3390\/nu14194077"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Moon SJ, Kim TH, Yoon SY, Chung JH, Hwang HJ. Relationship between stage of chronic kidney disease and sarcopenia in Korean aged 40 years and older using the Korea National Health and Nutrition Examination Surveys (KNHANES IV-2, 3, and V-1, 2), 2008-2011. PLOS ONE<\/i>, 10<\/b>, e0130740 (2015).","DOI":"10.1371\/journal.pone.0130740"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Duarte MP, Almeida LS, Neri SGR, Oliveira JS, Wilkinson TJ, Ribeiro HS, Lima RM. Prevalence of sarcopenia in patients with chronic kidney disease: a global systematic review and meta-analysis. J. Cachexia Sarcopenia Muscle<\/i>, 15<\/b>, 501\u2013512 (2024).","DOI":"10.1002\/jcsm.13425"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Cruz-Jentoft AJ, Bahat G, Bauer J, et al.<\/i> Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing<\/i>, 48<\/b>, 16\u201331 (2019).","DOI":"10.1093\/ageing\/afz046"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Arnal-G\u00f3mez A, Cebri\u00e0 i Iranzo MA, Tomas JM, Tortosa-Chuli\u00e1 MA, Balasch-Bernat M, Sentandreu-Ma\u00f1\u00f3 T, Forcano S, Cez\u00f3n-Serrano N. Using the updated EWGSOP2 definition in diagnosing sarcopenia in Spanish older adults: clinical approach. J. Clin. Med.<\/i>, 10<\/b>, 1018 (2021).","DOI":"10.3390\/jcm10051018"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Kitamura M, Takazono T, Yamaguchi K, Notomi S, Sawase K, Harada T, Funakoshi S, Mukae H, Nishino T. The impact of muscle mass loss and deteriorating physical function on prognosis in patients receiving hemodialysis. Sci. Rep.<\/i>, 11<\/b>, 22290 (2021).","DOI":"10.1038\/s41598-021-01581-z"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Sabatino A, Regolisti G, Benigno G, Di Mario F, Avesani CM, Fiaccadori E. Low skeletal muscle mass by computerized tomography is associated with increased mortality risk in end-stage kidney disease patients on hemodialysis. J. Nephrol.<\/i>, 35<\/b>, 545\u2013557 (2022).","DOI":"10.1007\/s40620-021-01167-y"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Sabatino A, D\u2019Alessandro C, Regolisti G, di Mario F, Guglielmi G, Bazzocchi A, Fiaccadori E. Muscle mass assessment in renal disease: the role of imaging techniques. Quant. Imaging Med. Surg.<\/i>, 10<\/b>, 1672\u20131686 (2020).","DOI":"10.21037\/qims.2020.03.05"},{"key":"17","unstructured":"17) Kirk B, Cawthon PM, Arai H, et al.<\/i> The conceptual definition of sarcopenia: Delphi consensus from the Global Leadership Initiative in Sarcopenia (GLIS). Age Ageing<\/i>, 53<\/b>, afae052 (2024)."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Huang N, Ge M, Liu X, et al.<\/i> A framework of biomarkers for skeletal muscle aging: a consensus statement by the Aging Biomarker Consortium. Life Med.<\/i>, 3<\/b>, lnaf001 (2025).","DOI":"10.1093\/lifemedi\/lnaf001"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Watanabe H, Imafuku T, Otagiri M, Maruyama T. Clinical implications associated with the posttranslational modification-induced functional impairment of albumin in oxidative stress-related diseases. J. Pharm. Sci.<\/i>, 106<\/b>, 2195\u20132203 (2017).","DOI":"10.1016\/j.xphs.2017.03.002"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Anraku M, Chuang VT, Maruyama T, Otagiri M. Redox properties of serum albumin. Biochim. Biophys. Acta, Gen. Subj.<\/i>, 1830<\/b>, 5465\u20135472 (2013).","DOI":"10.1016\/j.bbagen.2013.04.036"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Anraku M, Kitamura K, Shinohara A, Adachi M, Suenaga A, Maruyama T, Miyanaka K, Miyoshi T, Shiraishi N, Nonoguchi H, Otagiri M, Tomita K. Intravenous iron administration induces oxidation of serum albumin in hemodialysis patients. Kidney Int.<\/i>, 66<\/b>, 841\u2013848 (2004).","DOI":"10.1111\/j.1523-1755.2004.00813.x"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Nagumo K, Tanaka M, Chuang VT, Setoyama H, Watanabe H, Yamada N, Kubota K, Tanaka M, Matsushita K, Yoshida A, Jinnouchi H, Anraku M, Kadowaki D, Ishima Y, Sasaki Y, Otagiri M, Maruyama T. Cys34-cysteinylated human serum albumin is a sensitive plasma marker in oxidative stress-related chronic diseases. PLOS ONE<\/i>, 9<\/b>, e85216 (2014).","DOI":"10.1371\/journal.pone.0085216"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Imafuku T, Watanabe H, Oniki K, et al.<\/i> Cysteinylated albumin as a potential biomarker for the progression of kidney disease in patients with type 2 diabetes. Diabetes Care<\/i>, 44<\/b>, e115\u2013e117 (2021).","DOI":"10.2337\/dc20-3003"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Kato H, Watanabe H, Imafuku T, Arimura N, Fujita I, Noguchi I, Tanaka S, Nakano T, Tokumaru K, Enoki Y, Maeda H, Hino S, Tanaka M, Matsushita K, Fukagawa M, Maruyama T. Advanced oxidation protein products contribute to chronic kidney disease-induced muscle atrophy by inducing oxidative stress via<\/i> CD36\/NADPH oxidase pathway. J. Cachexia Sarcopenia Muscle<\/i>, 12<\/b>, 1832\u20131847 (2021).","DOI":"10.1002\/jcsm.12786"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Enoki Y, Watanabe H, Arake R, Sugimoto R, Imafuku T, Tominaga Y, Ishima Y, Kotani S, Nakajima M, Tanaka M, Matsushita K, Fukagawa M, Otagiri M, Maruyama T. Indoxyl sulfate potentiates skeletal muscle atrophy by inducing the oxidative stress-mediated expression of myostatin and atrogin-1. Sci. Rep.<\/i>, 6<\/b>, 32084 (2016).","DOI":"10.1038\/srep32084"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Sato E, Mori T, Mishima E, et al.<\/i> Metabolic alterations by indoxyl sulfate in skeletal muscle induce uremic sarcopenia in chronic kidney disease. Sci. Rep.<\/i>, 6<\/b>, 36618 (2016).","DOI":"10.1038\/srep36618"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Hou YC, Liao MT, Tsai KW, Zheng CM, Chiu HW, Lu KC. Indoxyl sulfate induced frailty in patients with end-stage renal disease by disrupting the PGC-1\u03b1-FNDC5 axis. Aging<\/i>, 15<\/b>, 11532\u201311545 (2023).","DOI":"10.18632\/aging.205141"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Lee SM, Han MY, Kim SH, Cha RH, Kang SH, Kim JC, An WS. Indoxyl sulfate might play a role in sarcopenia, while myostatin is an indicator of muscle mass in patients with chronic kidney disease: analysis from the recovery study. Toxins<\/i>, 14<\/b>, 660 (2022).","DOI":"10.3390\/toxins14100660"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Lin YL, Liu CH, Lai YH, Wang CH, Kuo CH, Liou HH, Hsu BG. Association of serum indoxyl sulfate levels with skeletal muscle mass and strength in chronic hemodialysis patients: a 2-year longitudinal analysis. Calcif. Tissue Int.<\/i>, 107<\/b>, 257\u2013265 (2020).","DOI":"10.1007\/s00223-020-00719-x"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Pircher T, Wackerhage H, Aszodi A, Kammerlander C, B\u00f6cker W, Saller MM. Hypoxic signaling in skeletal muscle maintenance and regeneration: a systematic review. Front. Physiol.<\/i>, 12<\/b>, 684899 (2021).","DOI":"10.3389\/fphys.2021.684899"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Nguyen TH, Conotte S, Belayew A, Decl\u00e8ves AE, Legrand A, Tassin A. Hypoxia and hypoxia-inducible factor signaling in muscular dystrophies: cause and consequences. Int. J. Mol. Sci.<\/i>, 22<\/b>, 7220 (2021).","DOI":"10.3390\/ijms22137220"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Xu J, Li R, Workeneh B, Dong Y, Wang X, Hu Z. Transcription factor FoxO1, the dominant mediator of muscle wasting in chronic kidney disease, is inhibited by microRNA-486. Kidney Int.<\/i>, 82<\/b>, 401\u2013411 (2012).","DOI":"10.1038\/ki.2012.84"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Reed SA, Sandesara PB, Senf SM, Judge AR. Inhibition of FoxO transcriptional activity prevents muscle fiber atrophy during cachexia and induces hypertrophy. FASEB J.<\/i>, 26<\/b>, 987\u20131000 (2012).","DOI":"10.1096\/fj.11-189977"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Tonelli M, Wiebe N, Bello A, Field CJ, Gill JS, Hemmelgarn BR, Holmes DT, Jindal K, Klarenbach SW, Manns BJ, Thadhani R, Kinniburgh D. Concentrations of trace elements and clinical outcomes in hemodialysis patients: a prospective cohort study. Clin. J. Am. Soc. Nephrol.<\/i>, 13<\/b>, 907\u2013915 (2018).","DOI":"10.2215\/CJN.11451017"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Nakano T, Kitazato Y, Ogawa T, Tokumaru K, Shintani Y, Yoshitake T, Yasuno K, Maeda H, Tanaka M, Matsushita K, Maruyama T, Watanabe H. Indoxyl sulfate contributes to selenium deficiency and renal ferroptosis by decreasing the expression of selenium transport protein Selenoprotein P. Kidney360<\/i>, 6<\/b>, 1448\u20131461 (2025).","DOI":"10.34067\/KID.0000000837"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) O\u2019Sullivan TF, Smith AC, Watson EL. Satellite cell function, intramuscular inflammation and exercise in chronic kidney disease. Clin. Kidney J.<\/i>, 11<\/b>, 810\u2013821 (2018).","DOI":"10.1093\/ckj\/sfy052"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Zhang L, Wang XH, Wang H, Du J, Mitch WE. Satellite cell dysfunction and impaired IGF-1 signaling cause CKD-induced muscle atrophy. J. Am. Soc. Nephrol.<\/i>, 21<\/b>, 419\u2013427 (2010).","DOI":"10.1681\/ASN.2009060571"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Elgaabari A, Imatomi N, Kido H, et al.<\/i> Age-related nitration\/dysfunction of myogenic stem cell activator HGF. Aging Cell<\/i>, 23<\/b>, e14041 (2024).","DOI":"10.1111\/acel.14041"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Higashihara T, Odawara M, Nishi H, Sugasawa T, Suzuki Y, Kametaka S, Inagi R, Nangaku M. Uremia impedes skeletal myocyte myomixer expression and fusogenic activity: implication for uremic sarcopenia. Am. J. Pathol.<\/i>, 194<\/b>, 759\u2013771 (2024).","DOI":"10.1016\/j.ajpath.2024.01.005"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Li CW, Yu K, Shyh-Chang N, et al.<\/i> Pathogenesis of sarcopenia and the relationship with fat mass: descriptive review. J. Cachexia Sarcopenia Muscle<\/i>, 13<\/b>, 781\u2013794 (2022).","DOI":"10.1002\/jcsm.12901"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Zheng G, Cao J, Wang XH, He W, Wang B. The gut microbiome, chronic kidney disease, and sarcopenia. Cell Commun. Signal.<\/i>, 22<\/b>, 558 (2024).","DOI":"10.1186\/s12964-024-01922-1"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Kir S, Komaba H, Garcia AP, Economopoulos KP, Liu W, Lanske B, Hodin RA, Spiegelman BM. PTH\/PTHrP receptor mediates cachexia in models of kidney failure and cancer. Cell Metab.<\/i>, 23<\/b>, 315\u2013323 (2016).","DOI":"10.1016\/j.cmet.2015.11.003"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Tanaka S, Watanabe H, Nakano T, Imafuku T, Kato H, Tokumaru K, Arimura N, Enoki Y, Maeda H, Tanaka M, Matsushita K, Fukagawa M, Maruyama T. Indoxyl sulfate contributes to adipose tissue inflammation through the activation of NADPH oxidase. Toxins<\/i>, 12<\/b>, 502 (2020).","DOI":"10.3390\/toxins12080502"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Arimura N, Watanabe H, Kato H, Imafuku T, Nakano T, Sueyoshi M, Chikamatsu M, Tokumaru K, Nagasaki T, Maeda H, Tanaka M, Matsushita K, Maruyama T. Advanced oxidation protein products contribute to chronic-kidney-disease-induced adipose inflammation through macrophage activation. Toxins<\/i>, 15<\/b>, 179 (2023).","DOI":"10.3390\/toxins15030179"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Chung LH, Liu ST, Huang SM, Salter DM, Lee HS, Hsu YJ. High phosphate induces skeletal muscle atrophy and suppresses myogenic differentiation by increasing oxidative stress and activating Nrf2 signaling. Aging<\/i>, 12<\/b>, 21446\u201321468 (2020).","DOI":"10.18632\/aging.103896"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Andres-Hernando A, Cicerchi C, Garcia GE, Orlicky DJ, Stenvinkel P, Johnson RJ, Lanaspa MA. Phosphate depletion in insulin-insensitive skeletal muscle drives AMPD activation and sarcopenia in chronic kidney disease. iScience<\/i>, 26<\/b>, 106355 (2023).","DOI":"10.1016\/j.isci.2023.106355"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Alcalde-Est\u00e9vez E, Sosa P, Asenjo-Bueno A, Plaza P, Valenzuela PL, Naves-D\u00edaz M, Olmos G, L\u00f3pez-Ongil S, Ruiz-Torres MP. Dietary phosphate restriction prevents the appearance of sarcopenia signs in old mice. J. Cachexia Sarcopenia Muscle<\/i>, 14<\/b>, 1060\u20131074 (2023).","DOI":"10.1002\/jcsm.13194"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Brautbar N, Carpenter C, Baczynski R, Kohan R, Massry SG. Impaired energy metabolism in skeletal muscle during phosphate depletion. Kidney Int.<\/i>, 24<\/b>, 53\u201357 (1983).","DOI":"10.1038\/ki.1983.125"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Chazot G, Lemoine S, Kocevar G, Kalbacher E, Sappey-Marinier D, Rouvi\u00e8re O, Juillard L. Intracellular phosphate and ATP depletion measured by magnetic resonance spectroscopy in patients receiving maintenance hemodialysis. J. Am. Soc. Nephrol.<\/i>, 32<\/b>, 229\u2013237 (2021).","DOI":"10.1681\/ASN.2020050716"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Nakagawa C, Inaba M, Ishimura E, Yamakawa T, Shoji S, Okuno S. Association of Increased serum ferritin with impaired muscle strength\/quality in hemodialysis patients. J. Ren. Nutr.<\/i>, 26<\/b>, 253\u2013257 (2016).","DOI":"10.1053\/j.jrn.2016.01.011"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Ikeda Y, Imao M, Satoh A, Watanabe H, Hamano H, Horinouchi Y, Izawa-Ishizawa Y, Kihira Y, Miyamoto L, Ishizawa K, Tsuchiya K, Tamaki T. Iron-induced skeletal muscle atrophy involves an Akt-forkhead box O3-E3 ubiquitin ligase-dependent pathway. J. Trace Elem. Med. Biol.<\/i>, 35<\/b>, 66\u201376 (2016).","DOI":"10.1016\/j.jtemb.2016.01.011"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Bose C, Megyesi J, Karaduta O, Singh SP, Swaminathan S, Shah SV. Iron chelation prevents age-related skeletal muscle sarcopenia in klotho gene mutant mice, a genetic model of aging. J. Cachexia Sarcopenia Muscle<\/i>, 16<\/b>, e13678 (2025).","DOI":"10.1002\/jcsm.13678"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Rineau E, Gueguen N, Procaccio V, Genevi\u00e8ve F, Reynier P, Henrion D, Lasocki S. Iron deficiency without anemia decreases physical endurance and mitochondrial complex I activity of oxidative skeletal muscle in the mouse. Nutrients<\/i>, 13<\/b>, 1056 (2021).","DOI":"10.3390\/nu13041056"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) Duan G, Li J, Duan Y, Zheng C, Guo Q, Li F, Zheng J, Yu J, Zhang P, Wan M, Long C. Mitochondrial iron metabolism: the crucial actors in diseases. Molecules<\/i>, 28<\/b>, 29 (2022).","DOI":"10.3390\/molecules28010029"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55) Ikizler TA, Burrowes JD, Byham-Gray LD, Campbell KL, Carrero JJ, Chan W, Fouque D, Friedman AN, Ghaddar S, Goldstein-Fuchs DJ, Kaysen GA, Kopple JD, Teta D, Yee-Moon Wang A, Cuppari L. KDOQI Clinical practice guideline for nutrition in CKD: 2020 update. Am. J. Kidney Dis.<\/i>, 76<\/b> (Suppl. 1), S1\u2013S107 (2020).","DOI":"10.1053\/j.ajkd.2020.05.006"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56) Kaspy MS, Hannaian SJ, Bell ZW, Churchward-Venne TA. The effects of branched-chain amino acids on muscle protein synthesis, muscle protein breakdown and associated molecular signalling responses in humans: an update. Nutr. Res. Rev.<\/i>, 37<\/b>, 273\u2013286 (2024).","DOI":"10.1017\/S0954422423000197"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57) Bowtell JL, Gelly K, Jackman ML, Patel A, Simeoni M, Rennie MJ. Effect of oral glutamine on whole body carbohydrate storage during recovery from exhaustive exercise. J. Appl. Physiol.<\/i>, 86<\/b>, 1770\u20131777 (1999).","DOI":"10.1152\/jappl.1999.86.6.1770"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58) Heiwe S, Jacobson SH. Exercise training for adults with chronic kidney disease. Cochrane Libr.<\/i>, 2011<\/b>, CD003236 (2011).","DOI":"10.1002\/14651858.CD003236.pub2"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59) Correa HL, Rosa TS, Santos RL, Mestrinho VM, Aquino TS, Santos WO, Neves RP, Deus LA, Reis AL, Barbosa JM, Araujo TB, Verhoeff R, Yatim K, Mendes D, Manfro RC, Borges TJ, Riella LV. The impact of different exercise modalities on chronic kidney disease: an umbrella review of meta-analyses. Front. Physiol.<\/i>, 15<\/b>, 1444976 (2025).","DOI":"10.3389\/fphys.2024.1444976"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60) Noor H, Reid J, Slee A. Resistance exercise and nutritional interventions for augmenting sarcopenia outcomes in chronic kidney disease: a narrative review. J. Cachexia Sarcopenia Muscle<\/i>, 12<\/b>, 1621\u20131640 (2021).","DOI":"10.1002\/jcsm.12791"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61) Cheema BS, Smith BC, Singh MA. A rationale for intradialytic exercise training as standard clinical practice in ESRD. Am. J. Kidney Dis.<\/i>, 45<\/b>, 912\u2013916 (2005).","DOI":"10.1053\/j.ajkd.2005.01.030"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62) Moeinzadeh F, Shahidi S, Shahzeidi S. Evaluating the effect of intradialytic cycling exercise on quality of life and recovery time in hemodialysis patients: a randomized clinical trial. J. Res. Med. Sci.<\/i>, 27<\/b>, 84 (2022).","DOI":"10.4103\/jrms.jrms_866_21"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63) Chaovarin C, Chaiprasert A, Satirapoj B, Nata N, Kaewput W, Tangwonglert T, Varothai N, Thimachai P, Tasanavipas P, Inkong P, Siriwattanasit N, Khrongkab N, Supasyndh O. Effect of intradialytic weight resistance training exercise in sarcopenic hemodialysis patients: a randomized controlled trial. Ther. Apher. Dial.<\/i>, 28<\/b>, 182\u2013191 (2024).","DOI":"10.1111\/1744-9987.14076"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64) Jandova T, Buend\u00eda-Romero A, Polanska H, Hola V, Rihova M, Vetrovsky T, Courel-Ib\u00e1\u00f1ez J, Steffl M. Long-term effect of exercise on irisin blood levels\u2014systematic review and meta-analysis. Healthcare<\/i>, 9<\/b>, 1438 (2021).","DOI":"10.3390\/healthcare9111438"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65) Saito Y, Chikenji TS, Matsumura T, Nakano M, Fujimiya M. Exercise enhances skeletal muscle regeneration by promoting senescence in fibro-adipogenic progenitors. Nat. Commun.<\/i>, 11<\/b>, 889 (2020).","DOI":"10.1038\/s41467-020-14734-x"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66) Enoki Y, Watanabe H, Arake R, Fujimura R, Ishiodori K, Imafuku T, Nishida K, Sugimoto R, Nagao S, Miyamura S, Ishima Y, Tanaka M, Matsushita K, Komaba H, Fukagawa M, Otagiri M, Maruyama T. Potential therapeutic interventions for chronic kidney disease-associated sarcopenia via<\/i> indoxyl sulfate-induced mitochondrial dysfunction. J. Cachexia Sarcopenia Muscle<\/i>, 8<\/b>, 735\u2013747 (2017).","DOI":"10.1002\/jcsm.12202"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67) Cha RH, Kang SH, Han MY, An WS, Kim SH, Kim JC. Effects of AST-120 on muscle health and quality of life in chronic kidney disease patients: results of RECOVERY study. J. Cachexia Sarcopenia Muscle<\/i>, 13<\/b>, 397\u2013408 (2022).","DOI":"10.1002\/jcsm.12874"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68) Han M, Song SH, Kim SH, Cha RH, Kang SH, An WS, Kim JC. Factors associated with gait speed: results from the RolE of AST120 (Renamezin) in sarCOpenia preVEntion in pRe-dialYsis chronic kidney disease patients (RECOVERY) study. Kidney Res. Clin. Pract.<\/i>, 45<\/b>, 416\u2013425 (2026).","DOI":"10.23876\/j.krcp.22.143"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69) Yamamoto S, Kazama JJ, Omori K, Matsuo K, Takahashi Y, Kawamura K, Matsuto T, Watanabe H, Maruyama T, Narita I. Continuous reduction of protein-bound uraemic toxins with improved oxidative stress by using the oral charcoal adsorbent AST-120 in haemodialysis patients. Sci. Rep.<\/i>, 5<\/b>, 14381 (2015).","DOI":"10.1038\/srep14381"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70) Sharma B, Yadav DK. L-Carnitine and chronic kidney disease: a comprehensive review on nutrition and health perspectives. J. Pers. Med.<\/i>, 13<\/b>, 298 (2023).","DOI":"10.3390\/jpm13020298"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71) Longo N, Frigeni M, Pasquali M. Carnitine transport and fatty acid oxidation. Biochim. Biophys. Acta Mol. Cell Res.<\/i>, 1863<\/b>, 2422\u20132435 (2016).","DOI":"10.1016\/j.bbamcr.2016.01.023"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72) Yano J, Kaida Y, Maeda T, Hashida R, Tonan T, Nagata S, Hazama T, Nakayama Y, Ito S, Kurokawa Y, Otome T, Shibata R, Tashiro K, Kakuma T, Matsuse H, Fukami K. L-carnitine supplementation vs.<\/i> cycle ergometer exercise for physical activity and muscle status in hemodialysis patients: a randomized clinical trial. Ther. Apher. Dial.<\/i>, 25<\/b>, 304\u2013313 (2021).","DOI":"10.1111\/1744-9987.13576"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73) Takashima H, Maruyama T, Abe M. Significance of levocarnitine treatment in dialysis patients. Nutrients<\/i>, 13<\/b>, 1219 (2021).","DOI":"10.3390\/nu13041219"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74) Cabello-Verrugio C, Morales MG, Rivera JC, Cabrera D, Simon F. Renin-angiotensin system: an old player with novel functions in skeletal muscle. Med. Res. Rev.<\/i>, 35<\/b>, 437\u2013463 (2015).","DOI":"10.1002\/med.21343"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75) Burks TN, Andres-Mateos E, Marx R, Mejias R, Van Erp C, Simmers JL, Walston JD, Ward CW, Cohn RD. Losartan restores skeletal muscle remodeling and protects against disuse atrophy in sarcopenia. Sci. Transl. Med.<\/i>, 3<\/b>, 82ra37 (2011).","DOI":"10.1126\/scitranslmed.3002227"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76) Takeda S, Kaji K, Nishimura N, Enomoto M, Fujimoto Y, Murata K, Takaya H, Kawaratani H, Moriya K, Namisaki T, Akahane T, Yoshiji H. Angiotensin receptor blockers potentiate the protective effect of branched-chain amino acids on skeletal muscle atrophy in cirrhotic rats. Mol. Nutr. Food Res.<\/i>, 65<\/b>, 2100526 (2021).","DOI":"10.1002\/mnfr.202100526"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77) Nakamura S, Miyachi Y, Shinjo A, Yokomizo H, Takahashi M, Nakatani K, Izumi Y, Otsuka H, Sato N, Sakamoto R, Miyazawa T, Bamba T, Ogawa Y. Improved endurance capacity of diabetic mice during SGLT2 inhibition: Role of AICARP, an AMPK activator in the soleus. J. Cachexia Sarcopenia Muscle<\/i>, 14<\/b>, 2866\u20132881 (2023).","DOI":"10.1002\/jcsm.13350"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78) Bamba R, Okamura T, Hashimoto Y, Majima S, Senmaru T, Ushigome E, Nakanishi N, Asano M, Yamazaki M, Takakuwa H, Hamaguchi M, Fukui M. Extracellular lipidome change by an SGLT2 inhibitor, luseogliflozin, contributes to prevent skeletal muscle atrophy in db\/db mice. J. Cachexia Sarcopenia Muscle<\/i>, 13<\/b>, 574\u2013588 (2022).","DOI":"10.1002\/jcsm.12814"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79) Nomura K, Takata T, Muramae N, Takahashi H, Abe K, Matsuda T. Comprehensive treatment with dapagliflozin in elderly chronic kidney disease patients: clinical efficacy and impact on body composition. J. Diabetes Complications<\/i>, 39<\/b>, 108951 (2025).","DOI":"10.1016\/j.jdiacomp.2025.108951"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80) Yabe D, Shiki K, Homma G, Meinicke T, Ogura Y, Seino Y. Efficacy and safety of the sodium-glucose co-transporter-2 inhibitor empagliflozin in elderly Japanese adults (\u226565\u2009years) with type 2 diabetes: a randomized, double-blind, placebo-controlled, 52-week clinical trial (EMPA-ELDERLY). Diabetes Obes. Metab.<\/i>, 25<\/b>, 3538\u20133548 (2023).","DOI":"10.1111\/dom.15249"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81) Qian FY, Li ZL, Guo YD, Gao HC, Gu LH, Le K, Xie CM, Wang B, Zhang ZJ. Hypoxia-inducible factor-prolyl hydroxylase inhibitor ameliorates myopathy in a mouse model of chronic kidney disease. Am. J. Physiol. Renal Physiol.<\/i>, 317<\/b>, F1265\u2013F1273 (2019).","DOI":"10.1152\/ajprenal.00260.2019"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82) Shin J, Nunomiya A, Kitajima Y, Dan T, Miyata T, Nagatomi R. Prolyl hydroxylase domain 2 deficiency promotes skeletal muscle fiber-type transition via<\/i> a calcineurin\/NFATc1-dependent pathway. Skelet. Muscle<\/i>, 6<\/b>, 5 (2016).","DOI":"10.1186\/s13395-016-0079-5"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83) Billin AN, Honeycutt SE, McDougal AV, Kerr JP, Chen Z, Freudenberg JM, Rajpal DK, Luo G, Kramer HF, Geske RS, Fang F, Yao B, Clark RV, Lepore J, Cobitz A, Miller R, Nosaka K, Hinken AC, Russell AJ. HIF prolyl hydroxylase inhibition protects skeletal muscle from eccentric contraction-induced injury. Skelet. Muscle<\/i>, 8<\/b>, 35 (2018).","DOI":"10.1186\/s13395-018-0179-5"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84) Hong Y, Lee JH, Jeong KW, Choi CS, Jun HS. Amelioration of muscle wasting by glucagon-like peptide-1 receptor agonist in muscle atrophy. J. Cachexia Sarcopenia Muscle<\/i>, 10<\/b>, 903\u2013918 (2019).","DOI":"10.1002\/jcsm.12434"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85) Iwai S, Kaji K, Nishimura N, Kubo T, Tomooka F, Shibamoto A, Suzuki J, Tsuji Y, Fujinaga Y, Kitagawa K, Namisaki T, Akahane T, Yoshiji H. Glucagon-like peptide-1 receptor agonist, semaglutide attenuates chronic liver disease-induced skeletal muscle atrophy in diabetic mice. Biochim. Biophys. Acta Mol. Basis Dis.<\/i>, 1869<\/b>, 166770 (2023).","DOI":"10.1016\/j.bbadis.2023.166770"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86) Sencan C, Dost FS, Ates Bulut E, Isik AT. DPP4 inhibitors as a potential therapeutic option for sarcopenia: a 6-month follow-up study in diabetic older patients. Exp. Gerontol.<\/i>, 164<\/b>, 111832 (2022).","DOI":"10.1016\/j.exger.2022.111832"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87) Ishii S, Nagai Y, Kato H, Fukuda H, Tanaka Y. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin on muscle mass and the muscle\/fat ratio in patients with type 2 diabetes. J. Clin. Med. Res.<\/i>, 12<\/b>, 122\u2013126 (2020).","DOI":"10.14740\/jocmr4078"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88) Ma XY, Chen FQ. Effects of anti-diabetic drugs on sarcopenia: Best treatment options for elderly patients with type 2 diabetes mellitus and sarcopenia. World J. Clin. Cases<\/i>, 9<\/b>, 10064\u201310074 (2021).","DOI":"10.12998\/wjcc.v9.i33.10064"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89) Nagayama A, Inokuchi T, Ashida K, Inada C, Homma T, Miyazaki H, Adachi T, Iwata S, Motomura S, Nomura M. Assessing the metabolic and physical effects of combined DPP4 and SGLT2 inhibitor therapy in patients with type-2 diabetes mellitus: an observational prospective pilot study. JMA J.<\/i>, 7<\/b>, 387\u2013400 (2024).","DOI":"10.31662\/jmaj.2023-0214"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90) Edey MM. Male sexual dysfunction and chronic kidney disease. Front. Med.<\/i>, 4<\/b>, 32 (2017).","DOI":"10.3389\/fmed.2017.00032"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91) Johansen KL, Mulligan K, Schambelan M. Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial. JAMA<\/i>, 281<\/b>, 1275\u20131281 (1999).","DOI":"10.1001\/jama.281.14.1275"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92) Dalton JT, Barnette KG, Bohl CE, Hancock ML, Rodriguez D, Dodson ST, Morton RA, Steiner MS. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J. Cachexia Sarcopenia Muscle<\/i>, 2<\/b>, 153\u2013161 (2011).","DOI":"10.1007\/s13539-011-0034-6"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93) Molina P, Carrero JJ, Bover J, Chauveau P, Mazzaferro S, Torres PU. Vitamin D, a modulator of musculoskeletal health in chronic kidney disease. J. Cachexia Sarcopenia Muscle<\/i>, 8<\/b>, 686\u2013701 (2017).","DOI":"10.1002\/jcsm.12218"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94) Beaudart C, Buckinx F, Rabenda V, Gillain S, Cavalier E, Slomian J, Petermans J, Reginster JY, Bruy\u00e8re O. The effects of vitamin D on skeletal muscle strength, muscle mass, and muscle power: a systematic review and meta-analysis of randomized controlled trials. J. Clin. Endocrinol. Metab.<\/i>, 99<\/b>, 4336\u20134345 (2014).","DOI":"10.1210\/jc.2014-1742"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95) Enoki Y, Nagai T, Hamamura Y, Osa S, Nakamura H, Taguchi K, Watanabe H, Maruyama T, Matsumoto K. The G protein-coupled receptor ligand apelin-13 ameliorates skeletal muscle atrophy induced by chronic kidney disease. J. Cachexia Sarcopenia Muscle<\/i>, 14<\/b>, 553\u2013564 (2023).","DOI":"10.1002\/jcsm.13159"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96) Zhang L, Rajan V, Lin E, Hu Z, Han HQ, Zhou X, Song Y, Min H, Wang X, Du J, Mitch WE. Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease. FASEB J.<\/i>, 25<\/b>, 1653\u20131663 (2011).","DOI":"10.1096\/fj.10-176917"},{"key":"97","doi-asserted-by":"crossref","unstructured":"97) Lee SJ. Targeting the myostatin signaling pathway to treat muscle loss and metabolic dysfunction. J. Clin. Invest.<\/i>, 131<\/b>, e148372 (2021).","DOI":"10.1172\/JCI148372"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98) Noguchi I, Maeda H, Kobayashi K, Nagasaki T, Kato H, Yanagisawa H, Wada N, Kanazawa G, Kaji T, Sakai H, Fujimaki S, Ono Y, Taguchi K, Chuang VTG, Saruwatari J, Otagiri M, Watanabe H, Maruyama T. Carbon monoxide-loaded cell therapy as an exercise mimetic for sarcopenia treatment. Free Radic. Biol. Med.<\/i>, 220<\/b>, 67\u201377 (2024).","DOI":"10.1016\/j.freeradbiomed.2024.04.231"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99) Giacomello E, Nicoletti C, Canato M, Toniolo L. Exercise mimetics in aging: suggestions from a systematic review. Nutrients<\/i>, 17<\/b>, 969 (2025).","DOI":"10.3390\/nu17060969"},{"key":"100","doi-asserted-by":"crossref","unstructured":"100) Caldiroli L, Molinari P, D\u2019Alessandro C, Cupisti A, Alfieri C, Castellano G, Vettoretti S. Osteosarcopenia in chronic kidney disease: an overlooked syndrome? J. Cachexia Sarcopenia Muscle<\/i>, 16<\/b>, e13787 (2025).","DOI":"10.1002\/jcsm.13787"},{"key":"101","doi-asserted-by":"crossref","unstructured":"101) Yu X, Sun S, Zhang S, Hao Q, Zhu B, Teng Y, Long Q, Li S, Lv Y, Yue Q, Lu S, Teng Z. A pooled analysis of the association between sarcopenia and osteoporosis. Medicine<\/i>, 101<\/b>, e31692 (2022).","DOI":"10.1097\/MD.0000000000031692"},{"key":"102","doi-asserted-by":"crossref","unstructured":"102) Zhao Z, Yan K, Guan Q, Guo Q, Zhao C. Mechanism and physical activities in bone-skeletal muscle crosstalk. Front. Endocrinol.<\/i>, 14<\/b>, 1287972 (2024).","DOI":"10.3389\/fendo.2023.1287972"},{"key":"103","doi-asserted-by":"crossref","unstructured":"103) Liu H, Wada A, Le I, Le PT, Lee AWF, Zhou J, Gori F, Baron R, Rosen CJ. PTH regulates osteogenesis and suppresses adipogenesis through Zfp467 in a feed-forward, PTH1R-cyclic AMP-dependent manner. eLife<\/i>, 12<\/b>, e83345 (2023).","DOI":"10.7554\/eLife.83345"},{"key":"104","doi-asserted-by":"crossref","unstructured":"104) Yu B, Huo L, Liu Y, Deng P, Szymanski J, Li J, Luo X, Hong C, Lin J, Wang CY. PGC-1\u03b1 controls skeletal stem cell fate and bone-fat balance in osteoporosis and skeletal aging by inducing TAZ. Cell Stem Cell<\/i>, 23<\/b>, 193\u2013209.e195 (2018).","DOI":"10.1016\/j.stem.2018.06.009"},{"key":"105","doi-asserted-by":"crossref","unstructured":"105) Zhang J, Wu L, Wang P, Pan Y, Dong X, Jia L, Zhang A. Prevalence of cognitive impairment and its predictors among chronic kidney disease patients: a systematic review and meta-analysis. PLOS ONE<\/i>, 19<\/b>, e0304762 (2024).","DOI":"10.1371\/journal.pone.0304762"},{"key":"106","doi-asserted-by":"crossref","unstructured":"106) Otobe Y, Hiraki K, Hotta C, Nishizawa H, Izawa KP, Taki Y, Imai N, Sakurada T, Shibagaki Y. Mild cognitive impairment in older adults with pre-dialysis patients with chronic kidney disease: Prevalence and association with physical function. Nephrology<\/i>, 24<\/b>, 50\u201355 (2019).","DOI":"10.1111\/nep.13173"},{"key":"107","doi-asserted-by":"crossref","unstructured":"107) Andrews TD, Day GS, Irani SR, Kanekiyo T, Hickson LJ. Uremic toxins, CKD, and cognitive dysfunction. J. Am. Soc. Nephrol.<\/i>, 36<\/b>, 1208\u20131226 (2025).","DOI":"10.1681\/ASN.0000000675"},{"key":"108","doi-asserted-by":"crossref","unstructured":"108) Han X, Ashraf M, Tipparaju SM, Xuan W. Muscle-Brain crosstalk in cognitive impairment. Front. Aging Neurosci.<\/i>, 15<\/b>, 1221653 (2023).","DOI":"10.3389\/fnagi.2023.1221653"},{"key":"109","doi-asserted-by":"crossref","unstructured":"109) Wang L, Bian X, Liu L, He Q, Xu J, Chen X, Ye H, Yang J, Jiang L. Association between cognitive function and skeletal muscle in patients undergoing maintenance hemodialysis. Front. Endocrinol.<\/i>, 15<\/b>, 1324867 (2024).","DOI":"10.3389\/fendo.2024.1324867"},{"key":"110","unstructured":"110) Wagner CA, Massy ZA, Capasso G, Mattace-Raso F, Pepin M, Bobot M, Zoccali C, Ferreira AC, Hoorn EJ, Imenez Silva PH, Unwin RJ, Pesic V. Translational research on cognitive impairment in chronic kidney disease. Nephrol. Dial. Transplant.<\/i>, 40<\/b>, 621\u2013631 (2025)."},{"key":"111","doi-asserted-by":"crossref","unstructured":"111) Bobot M, Thomas L, Moyon A, Fernandez S, McKay N, Balasse L, Garrigue P, Brige P, Chopinet S, Poitevin S, C\u00e9rini C, Brunet P, Dignat-George F, Burtey S, Guillet B, Hache G. Uremic toxic blood-brain barrier disruption mediated by AhR activation leads to cognitive impairment during experimental renal dysfunction. J. Am. Soc. Nephrol.<\/i>, 31<\/b>, 1509\u20131521 (2020).","DOI":"10.1681\/ASN.2019070728"},{"key":"112","doi-asserted-by":"crossref","unstructured":"112) Yang H, Qi L, Pei D. Effect of psychosocial interventions for depression in adults with chronic kidney disease: a systematic review and meta-analysis. BMC Nephrol.<\/i>, 25<\/b>, 17 (2024).","DOI":"10.1186\/s12882-023-03447-0"},{"key":"113","doi-asserted-by":"crossref","unstructured":"113) Balakrishnan R, Thurmond DC. Mechanisms by which skeletal muscle myokines ameliorate insulin resistance. Int. J. Mol. Sci.<\/i>, 23<\/b>, 4636 (2022).","DOI":"10.3390\/ijms23094636"},{"key":"114","doi-asserted-by":"crossref","unstructured":"114) Jodeiri Farshbaf M, Alvi\u00f1a K. Multiple roles in neuroprotection for the exercise derived myokine irisin. Front. Aging Neurosci.<\/i>, 13<\/b>, 649929 (2021).","DOI":"10.3389\/fnagi.2021.649929"},{"key":"115","doi-asserted-by":"crossref","unstructured":"115) Zhao R. Irisin at the crossroads of inter-organ communications: challenge and implications. Front. Endocrinol.<\/i>, 13<\/b>, 989135 (2022).","DOI":"10.3389\/fendo.2022.989135"},{"key":"116","doi-asserted-by":"crossref","unstructured":"116) Xing S, Ma Y, Song B, Bai M, Wang K, Song W, Cao T, Guo C, Zhang Y, Wang Z, Wang Y. Irisin reshapes bone metabolic homeostasis to delay age-related osteoporosis by regulating the multipotent differentiation of BMSCs via<\/i> Wnt pathway. Front. Mol. Biosci.<\/i>, 11<\/b>, 1524978 (2025).","DOI":"10.3389\/fmolb.2024.1524978"},{"key":"117","doi-asserted-by":"crossref","unstructured":"117) Wrann CD, White JP, Salogiannnis J, Laznik-Bogoslavski D, Wu J, Ma D, Lin JD, Greenberg ME, Spiegelman BM. Exercise induces hippocampal BDNF through a PGC-1\u03b1\/FNDC5 pathway. Cell Metab.<\/i>, 18<\/b>, 649\u2013659 (2013).","DOI":"10.1016\/j.cmet.2013.09.008"},{"key":"118","doi-asserted-by":"crossref","unstructured":"118) Madhu LN, Somayaji Y, Shetty AK. Promise of irisin to attenuate cognitive dysfunction in aging and Alzheimer\u2019s disease. Ageing Res. Rev.<\/i>, 78<\/b>, 101637 (2022).","DOI":"10.1016\/j.arr.2022.101637"},{"key":"119","doi-asserted-by":"crossref","unstructured":"119) Li X, Lindholm B. The role of irisin in kidney diseases. Clin. Chim. Acta<\/i>, 554<\/b>, 117756 (2024).","DOI":"10.1016\/j.cca.2023.117756"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/6\/49_b26-00057\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T03:33:57Z","timestamp":1780716837000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/6\/49_b26-00057\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":119,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b26-00057","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"article-number":"b26-00057"}}